David Siewers Net Worth

The estimated Net Worth of David Siewers is at least $343 Mille dollars as of 20 September 2017. David Siewers owns over 16,424 units of Selecta Biosciences Inc stock worth over $12,522 and over the last 8 years David sold SELB stock worth over $330,760.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Siewers SELB stock SEC Form 4 insiders trading

David has made over 4 trades of the Selecta Biosciences Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently David exercised 16,424 units of SELB stock worth $10,347 on 20 September 2017.

The largest trade David's ever made was exercising 16,424 units of Selecta Biosciences Inc stock on 20 September 2017 worth over $10,347. On average, David trades about 5,769 units every 12 days since 2016. As of 20 September 2017 David still owns at least 14,230 units of Selecta Biosciences Inc stock.

You can see the complete history of David Siewers stock trades at the bottom of the page.

What's David Siewers's mailing address?

David's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL STREET, BUILDING ONE, WATERTOWN, MA, 02472.

Insiders trading at Selecta Biosciences Inc

Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit... e Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.

What does Selecta Biosciences Inc do?

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat

Complete history of David Siewers stock trades at Selecta Biosciences Inc

Selecta Biosciences Inc executives and stock owners

Selecta Biosciences Inc executives and other stock owners filed with the SEC include:

• Carsten Brunn,
  President, Chief Executive Officer, Director
• Lloyd Johnston,
  Chief Operating Officer, Senior Vice President - Research & development
• Dr. Carsten Brunn,
  CEO, Pres & Director
• Dr. Peter G. Traber M.D.,
  Chief Medical Officer
• Patrick Zenner,
  Independent Director
• Timothy Springer,
  Independent Director
• Timothy Barabe,
  Independent Director
• Aymeric Sallin,
  Independent Director
• Scott Myers,
  Independent Director
• Carrie Cox,
  Independent Chairman of the Board
• Lee Stern,
  IR Contact Officer
• Goran Ando,
  Independent Director
• Bradford Dahms,
  Chief Financial Officer, Principal Accounting Officer
• Takashi Kishimoto,
  Chief Scientific Officer
• Kristen Baldwin,
  Chief People Officer
• Dr. Takashi Kei Kishimoto Ph.D.,
  Chief Scientific Officer
• Dr. Lloyd Johnston,
  COO and Sr. VP of R&D
• Kevin Tan,
  Chief Financial Officer
• Ann K. Donohue,
  VP of Fin., Interim Principal Financial Officer & Principal Accounting Officer
• Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D.,
  Co-Founder and Co-Chair of the Scientific Advisory Board
• Omid Farokhzad,
  Director
• Peter Barton Hutt,
  Director
• Edwin M Jr Kania,
  Director
• Peter Keller,
  Chief Business Officer
• Advisors Llc Orbi Med Capit...,
  
• Rusnano,
  10% owner
• Carl L Gordon,
  Director
• Capital I2 Bf Netherlands, ...,
  
• University Partners Ii, L.P...,
  
• Management Ltd Nanodimensio...,
  
• Partners, Llc Leukon Invest...,
  
• Venture Management Co. V, L...,
  
• Ventures Fund 2007, L.P.Fla...,
  
• Earl Sands,
  Chief Medical Officer
• David Siewers,
  Chief Financial Officer
• David Abraham,
  CCO, GC and Corp. Sec.
• Nishan M De Silva,
  Director
• Werner Cautreels,
  President and CEO
• Amir Nashat,
  Director
• John Harold Leaman,
  CFO, Treas. & Hd Corp Strategy
• Stephen Smolinski,
  Chief Commercial Officer
• Elona Kogan,
  General Counsel
• Peter G Traber,
  Chief Medical Officer
• Alison D. Schecter,
  Chief Medical Officer
• Kevin Tan,
  Chief Financial Officer
• Blaine Davis,
  Chief Financial Officer